Home
Resources
Follow portfolio news
...

Cleerly joins forces with Cardiac Care Alliance to revolutionize cardiovascular disease detection

Published on
4/7/2025
Amended on
25/3/2026
0
minute(s)
Odyssey 2025
Cleerly
Like many players in the healthcare sector, Cleerly is leveraging artificial intelligence to refine its diagnostic capabilities. This pioneering U.S. company in cardiovascular risk prevention is part of the Vintage FPCI Altaroc Odyssey portfolio. Through a partnership with Cardiac Care Alliance, which works closely with healthcare experts and hospitals, Cleerly aims to transform cardiac medicine.
By
Antoine Orsoni
Antoine Orsoni
Cleerly joins forces with Cardiac Care Alliance to revolutionize cardiovascular disease detection
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
This article has been automatically translated. We apologize per inaccuracies or translation errors.

Two pillars of cardiovascular disease detection and treatment come together. Their goal is to integrate Cleerly's advanced AI-based coronary artery assessment technology (which irrigates the heart) with the Cardiac Care Alliance cardiovascular care network in Texas and California. The latter, by facilitating rapid access to quality care for providers, insurers and patients, improves outcomes while optimizing costs.

Cardiac Care Alliance is committed to proactive, personalized and patient-centered cardiovascular medicine, aimed at making care more seamless and accessible. The aim of this partnership is for symptomatic patients to benefit, where relevant, from an assessment via Cleerly prior to any cardiac catheterization procedure (insertion of a small tube into an artery to explore the heart). This will enable only those patients who need the procedure to be referred to the catheterization laboratory, while avoiding unnecessary examinations and additional costs for patients who do not. Deployment will begin with cardiology practices in Texas, before being rolled out more widely across the US.

"By detecting coronary disease more accurately and non-invasively, we can guide personalized treatment decisions that improve outcomes while reducing costs. At a time when cardiovascular spending could exceed $1 trillion by 2035 as the population ages, and re-hospitalizations for cardiac conditions are among the most frequent and costly for Medicare [the US federal health insurance program], we are focusing our efforts on a simple fact: many cardiovascular pathologies are treatable if detected early - potentially saving a large number of lives," explains Dr James Min, Cleerly's founder and CEO.

Cleerly's mission is to redefine the standards of care for heart-related diseases. Thanks to its AI-powered solutions approved by the FDA (Food and Drug Administration, which regulates and authorizes the marketing of many healthcare products in the USA), Cleerly enables in-depth characterization of coronary artery disease based on non-invasive imaging. Its scientific approach is based on the analysis of millions of images from over 40,000 patients.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
North America
Healthcare
Welcome to Altaroc
To provide you with a tailored experience, please complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
YOUR INVESTOR PROFILE
Financial intermediary or professional investor
Financial advisors, wealth managers, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced investor or Altaroc investor
Private investors who have already invested with Altaroc or who have a minimum investment capacity of €100,000.
Private investors who have previously invested in Altaroc who have a minimum investment capacity of 200,000 euros.
Non-professional (retail) investor
Individual investors with an investment capacity below €100,000.
Retail investors with an investment capacity of less than 200,000 euros.
Institutional investor
Pension funds, retirement schemes, asset management companies, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.